Skip to content
Subscriber Only

Sell, Spin or Keep? Pfizer in a Quandary on Advil-Chapstick Unit

  • Pharmaceutical giant is weighing spinoff or keeping business
  • Seismic retail changes have squeezed consumer-health profits
Video player cover image

Pfizer in a Quandary Over Consumer-Health Business

Updated on

Pfizer Inc.’s attempt to unload its consumer-health business fizzled, but hanging on to the division a while longer may not be a headache for the world’s largest drugmaker.

British pharmaceutical giant GlaxoSmithKline Plc, the final prospective buyer, withdrew from the bidding Friday, ending for now a sale process that began in October. Reckitt Benckiser Group Plc, another potential buyer, pulled out earlier this week.